Search clinical trials for: BIIB017 (PEGylated Interferon Beta-1a)

Total 613 results

Biogen

Completed

A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers

Healthy

United States
Biogen

Completed

Plegridy Observational Program (POP)

Relapsing Forms of Multiple Sclerosis

United States, Italy, Switzerland, Canada, Australia, Germany, Spain, France, Portugal, Netherlands, United Kingdom, Denmark, Austria, Ireland
Biogen

Completed

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (ATTAIN)

Relapsing Multiple Sclerosis

United States, Croatia, Russian Federation, India, Spain, New Zealand, Canada, Belgium, Netherlands, Bulgaria, Serbia, Greece, Ukraine, Mexico, Georgia, Colombia, Germany, Poland, United Kingdom, Czech Republic, France, Chile, Romania, Eston... and more
Biogen

Completed

Plegridy Satisfaction Study in Participants (PLATINUM)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Johns Hopkins University
Biogen

Withdrawn

Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis
Biogen

Withdrawn

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy (Frequency)

Relapsing Multiple Sclerosis
Biogen

Completed

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis (ADVANCE)

Relapsing Multiple Sclerosis

United States, Germany, Russian Federation, India, New Zealand, Spain, Belgium, Colombia, Canada, Bulgaria, Serbia, Greece, Peru, Ukraine, Poland, United Kingdom, Croatia, France, Romania, Chile, Czech Republic, Mexico, Estonia, Georgia, Latv... and more
Biogen

Completed

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (PLENO)

Relapsing Remitting Multiple Sclerosis

Portugal
Biogen

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Spain, Germany, Croatia, Turkey, Saudi Arabia, Hungary, Belgium, Australia, France, Portugal, Slovakia, United States, Bulgaria, Greece, Kuwait, Russian Federation, Tunisia, Italy, Argentina, Czechia, Israel, Serbia
Cinnagen

Completed

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis (RRMS)

Iran, Islamic Republic of
Biogen

Completed

Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers

Multiple Sclerosis | Healthy

United States
Biocad

Completed

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Healthy

Russian Federation
Biogen

Completed

Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.

Healthy

United Kingdom
Biocad

Completed

Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Russian Federation
Biogen

Withdrawn

Brimonidine Tartrate for the Treatment of Injection Related Erythema (BRITE)

Relapsing-Remitting Multiple Sclerosis (RRMS)
Biogen

Completed

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)

Multiple Sclerosis

United States, Spain, Hungary, Serbia, Canada, France, Poland, Russian Federation, Netherlands, Czech Republic, Italy, United Kingdom
Biogen
AbbVie

Completed

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis ((DECIDE))

Relapsing-Remitting Multiple Sclerosis

Sweden, United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Ukraine, Denmark, Finland, Romania, Canada, France, Hungary, Israel, Switzerland, Serbia, India, Mexico, Poland, Georgia, Ireland, Argentin... and more
Biocad

Completed

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Centre Hospitalier Universitaire Vaudois
BioPartners GmbH

Completed

Phase I BP Interferon (IFN) Beta-004

Multiple Sclerosis, Relapsing-Remitting
EMD Serono
Merck Serono International SA

Completed

Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis

Ulcerative Colitis

Sweden, Germany, Netherlands, Israel, Singapore, Switzerland, United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR)

Relapsing-Remitting Multiple Sclerosis

Germany, Estonia, Latvia, Lithuania, Finland, Austria, Denmark, Netherlands, Portugal, Switzerland, Norway, Italy
Merck KGaA, Darmstadt, Germany
Merck spol.s.r.o., Czech Republic

Completed

Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® (SKORE)

Multiple Sclerosis, Relapsing-Remitting

Czech Republic
Biogen
AMS Advanced Medical Services GmbH

Completed

A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis (PERFECT)

Multiple Sclerosis, Relapsing-Remitting

Germany
Biogen

Completed

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) (ALLOW)

Relapsing Multiple Sclerosis

United States
Biogen

Completed

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

United States, Australia, Canada, United Kingdom
EMD Serono
Merck Pte. Ltd., Singapore

Completed

A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects

Hepatitis C
Biogen

Recruiting

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Multiple Sclerosis

Spain, Ireland, United States, Germany
Cinnagen

Completed

Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)

Healthy | Bioequivalence

Finland
Biogen

Completed

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

Multiple Sclerosis

United States
S. Andrea Hospital

Unknown

Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients

Multiple Sclerosis

Italy
Biogen

Completed

Open-Label Safety Extension Study of Avonex

Multiple Sclerosis
Biogen

Completed

Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers

Multiple Sclerosis
Biogen

Completed

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy (SAFE)

Multiple Sclerosis

Sweden
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis

Multiple Sclerosis

Germany
Synairgen Research Ltd.

Completed

A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone (RETURN)

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone (REMAIN)

Multiple Sclerosis, Relapsing-Remitting
EMD Serono
Pfizer

Completed

RNF and Betaseron® Tolerability Study (REFORMS)

Relapsing Remitting Multiple Sclerosis (RRMS)

United States
PD Dr. Marcus Müller
BfARM, Bonn; DZNE, Bonn

Unknown

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RESI)

Relapsing-remitting Multiple Sclerosis

Germany
Biogen

Completed

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Active Ulcerative Colitis

United States, Canada, Czech Republic, Hungary, Poland, Russian Federation, Slovakia
Merck KGaA, Darmstadt, Germany
Merck Serono Australia Pty Ltd

Completed

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (ReNew)

Multiple Sclerosis

Australia
National Institute of Neurological Disorders and...

Completed

Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)

Tropical Spastic Paraparesis | Spinal Cord Disease | HTLV-I Infection

United States
Merck KGaA, Darmstadt, Germany

Completed

Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis
Biogen

Completed

Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen (SFERA)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Clinical Isolated Syndrome (CIS)

Czech Republic, Switzerland
EMD Serono
Pfizer

Completed

Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis (RNF)

Multiple Sclerosis

United States
Biogen

Completed

Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

Multiple Sclerosis | Pregnancy | Prenatal Exposure Delayed Effects

United States
Synairgen Research Ltd.

Completed

Comparing Efficacy and Safety of Inhaled SNG001 to Placebo

Asthma

United Kingdom
EMD Serono

Terminated

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate (RESOunD)

Multiple Sclerosis

United States
Trio Medicines Ltd.
Biogen

Completed

Avonex®: Safety, Blood Levels and Effects (C-851)

Multiple Sclerosis (MS)

United Kingdom

3

Subscribe